CLPT

Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.

AngioDynamics reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.10 loss by 60%, but missed revenue expectations with $80.92 million versus the estimated $81.85 million. The medical device company has a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Instruments industry ranks in the top 39% of Zacks industries.